With strong 1-year returns and upside potential, Gossamer Bio, Inc. (NASDAQ:GOSS) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026. Amid the company’s continued ...

Late last month, Gossamer Bio filed to raise up to $230 million in a fixed-price IPO so it could go public despite the partial shutdown of the U.S. government. Now that the government has reopened, ...

Gossamer Bio stock has maintained its consensus analyst price target at $9.50 per share, even as analysts adjust their outlooks in response to the company's progress on key clinical milestones. A ...

Gossamer Bio advances the Feb. 2026 PROSERA Phase 3 readout for seralutinib in PAH, with expanded endpoints and a new ILD trial. Learn why GOSS stock is a hold.

Gossamer bio will end the extension of a phase 2 study for a small molecule ulcerative colitis med that was found to be ineffective—the second time in 18 months the company has seen a top program fail ...

Gossamer Bio has experienced numerous ups and downs over the years, including a clinical setback and significant staff reductions. Now, as it pursues potential approval for a heart drug, the company ...

We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media. In this article, we are going to ...

The Gossamer Gear Whisper is one of the most impossible-looking tents I’ve ever seen. It’s a veritable palace for one person that packs up to the size of an oversized nalgene. There is also something ...

SAN DIEGO, August 05, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...

Shelia Gujrathi is the CEO and cofounder of Gossamer Bio, which went public on February 8, raising over $270 million. When Celgene bought Receptos in 2015, Dr. Sheila Gujrathi, who was chief medical ...